What is Prapela?
Prapela operates at the intersection of medical technology and pediatric healthcare, focusing on the development of innovative solutions for newborns. The company is best known for its FDA-authorized vibrating bassinet pad, a pioneering device engineered to treat Neonatal Opioid Withdrawal Syndrome (NOWS). By facilitating gentle stimulation and supporting skin-to-skin care, the technology offers a critical alternative to traditional pharmacological treatments. Beyond its primary application in managing withdrawal symptoms, Prapela is actively engaged in clinical research to evaluate the efficacy of its platform in improving respiratory outcomes and oxygenation levels for preterm infants, thereby establishing a robust footprint in the neonatal intensive care market.
How much funding has Prapela raised?
Prapela has raised a total of $36K across 1 funding round:
Debt
$36K
Debt (2021): $36K with participation from PPP
Key Investors in Prapela
PPP
Public-Private Partnership
What's next for Prapela?
With the recent infusion of capital, Prapela is poised to accelerate its commercialization strategy and expand the reach of its medical devices within hospitals and healthcare facilities across the United States. The company's strategic roadmap likely involves scaling manufacturing capabilities to meet institutional demand and advancing its ongoing clinical trials. By prioritizing evidence-based outcomes, Prapela aims to solidify its position as a leader in neonatal health technology, potentially diversifying its product pipeline to address additional respiratory and developmental challenges in early-stage pediatric care. The firm remains focused on bridging the gap between clinical necessity and technological innovation to improve long-term health trajectories for newborns.
See full Prapela company page
